Omniome
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | N/A | Seed | |
N/A | N/A | Series A | |
$60.0m | Series B | ||
$60.0m | Series C | ||
$800m Valuation: $800m | Acquisition | ||
Total Funding | $120m |
Related Content
Recent News about Omniome
EditOmniome operates at the cutting edge of DNA sequencing technology, leveraging advancements in nanotechnology and genomics to deliver unparalleled solutions. The company primarily serves research institutions, healthcare providers, and biotech firms that require precise and efficient DNA sequencing capabilities. Operating in the rapidly growing genomics market, Omniome's business model revolves around the development and sale of high-performance sequencing instruments and consumables. Revenue is generated through the sale of these products, as well as through service contracts and maintenance agreements. The company is known for its collaborative environment, bringing together a team of skilled scientists and engineers dedicated to pushing the boundaries of what's possible in DNA sequencing.
Keywords: DNA sequencing, nanotechnology, genomics, research institutions, healthcare, biotech, sequencing instruments, consumables, innovation, collaboration.